The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.

Adrian S, Scherzinger A, Sanyal A, Lake JE, Falutz J, Dubé MP, Stanley T, Grinspoon S, Mamputu JC, Marsolais C, Brown TT, Erlandson KM

The Journal of frailty & aging1 Jan 2019Cited by 13 (Europe PMC)

PMID31237318PMCIDPMC6766405DOI10.14283/jfa.2018.45PepBankPUB-31237318

Read at source PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with HIV and abdominal obesity, tesamorelin responders (visceral fat decrease of ≥8%) had greater increases than placebo participants in the density of four truncal muscle groups.
In plain wordsIn adults with HIV and abdominal obesity, people who responded to tesamorelin had a larger rise in trunk muscle density than people on placebo.
Peptide
Tesamorelin
Outcome
IncreaseDensity of four truncal muscle groups
Study
n = 341
Comparator
Placebo
Analysis
Exploratory
Outcome group
Body composition · Musculoskeletal
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Measurements
Density coefficient
1.56 to 4.86 Hounsfield units
four truncal muscle groups
Source sentences
Summary
tesamorelin was associated with significantly greater increases in density of four truncal muscle groups (coefficient 1.56-4.86 Hounsfield units; all p<0.005)
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary, exploratory analysis of two previously completed randomized (2:1), clinical trials.
Summary · context
Tesamorelin responders (n=193) and placebo (n=148) participants with available images were similar at baseline; most were Caucasian (83%) and male (87%).
Report a problemFND-3123731801
02HumanRandomized controlled trialEfficacy outcome
In adults with HIV and abdominal obesity, tesamorelin responders (visceral fat decrease of ≥8%) had greater increases than placebo participants in the lean density of the anterolateral/abdominal muscles.
In plain wordsIn adults with HIV and abdominal obesity, people who responded to tesamorelin had a larger rise in lean abdominal muscle density than people on placebo.
Peptide
Tesamorelin
Outcome
IncreaseLean density of anterolateral/abdominal muscles
Study
n = 341
Comparator
Placebo
Analysis
Exploratory
Outcome group
Body composition · Musculoskeletal
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Measurements
Lean density coefficient
1.39 Hounsfield units
anterolateral/abdominal muscles
Source sentences
Summary
In models adjusted for baseline differences and treatment arm, tesamorelin was associated with significantly greater increases in density of four truncal muscle groups (coefficient 1.56-4.86 Hounsfield units; all p<0.005), and the lean anterolateral/abdominal and rectus muscles (1.39 and 1.78 Hounsf…
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary, exploratory analysis of two previously completed randomized (2:1), clinical trials.
Summary · context
Tesamorelin responders (n=193) and placebo (n=148) participants with available images were similar at baseline; most were Caucasian (83%) and male (87%).
Report a problemFND-3123731802
03HumanRandomized controlled trialEfficacy outcome
In adults with HIV and abdominal obesity, tesamorelin responders (visceral fat decrease of ≥8%) had greater increases than placebo participants in the lean density of the rectus muscles.
In plain wordsIn adults with HIV and abdominal obesity, people who responded to tesamorelin had a larger rise in lean rectus muscle density than people on placebo.
Peptide
Tesamorelin
Outcome
IncreaseLean density of rectus muscles
Study
n = 341
Comparator
Placebo
Analysis
Exploratory
Outcome group
Body composition · Musculoskeletal
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Measurements
Lean density coefficient
1.78 Hounsfield units
rectus muscles
Source sentences
Summary
In models adjusted for baseline differences and treatment arm, tesamorelin was associated with significantly greater increases in density of four truncal muscle groups (coefficient 1.56-4.86 Hounsfield units; all p<0.005), and the lean anterolateral/abdominal and rectus muscles (1.39 and 1.78 Hounsf…
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary, exploratory analysis of two previously completed randomized (2:1), clinical trials.
Summary · context
Tesamorelin responders (n=193) and placebo (n=148) participants with available images were similar at baseline; most were Caucasian (83%) and male (87%).
Report a problemFND-3123731803
04HumanRandomized controlled trialEfficacy outcome
In adults with HIV and abdominal obesity, tesamorelin responders (visceral fat decrease of ≥8%) had a greater increase than placebo participants in the total area of the rectus muscles.
In plain wordsIn adults with HIV and abdominal obesity, people who responded to tesamorelin had a larger rise in rectus muscle area than people on placebo.
Peptide
Tesamorelin
Outcome
IncreaseTotal area of rectus muscles
Study
n = 341
Comparator
Placebo
Analysis
Exploratory
Outcome group
Body composition · Musculoskeletal
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Measurements
Total area increase
0.44 centimeters2
rectus muscles
Source sentences
Summary
Significant increases were also seen in total area of the rectus and psoas muscles (0.44 and 0.46 centimeters2; p<0.005), and in the lean muscle area of all four truncal muscle groups (0.64-1.08 centimeters2; p<0.005).
3 context sentences(design, population, supporting numbers)
Summary · context
compared to placebo.
Summary · context
Secondary, exploratory analysis of two previously completed randomized (2:1), clinical trials.
Summary · context
Tesamorelin responders (n=193) and placebo (n=148) participants with available images were similar at baseline; most were Caucasian (83%) and male (87%).
Report a problemFND-3123731804
05HumanRandomized controlled trialEfficacy outcome
In adults with HIV and abdominal obesity, tesamorelin responders (visceral fat decrease of ≥8%) had a greater increase than placebo participants in the total area of the psoas muscles.
In plain wordsIn adults with HIV and abdominal obesity, people who responded to tesamorelin had a larger rise in psoas muscle area than people on placebo.
Peptide
Tesamorelin
Outcome
IncreaseTotal area of psoas muscles
Study
n = 341
Comparator
Placebo
Analysis
Exploratory
Outcome group
Body composition · Musculoskeletal
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Measurements
Total area increase
0.46 centimeters2
psoas muscles
Source sentences
Summary
Significant increases were also seen in total area of the rectus and psoas muscles (0.44 and 0.46 centimeters2; p<0.005), and in the lean muscle area of all four truncal muscle groups (0.64-1.08 centimeters2; p<0.005).
3 context sentences(design, population, supporting numbers)
Summary · context
compared to placebo.
Summary · context
Secondary, exploratory analysis of two previously completed randomized (2:1), clinical trials.
Summary · context
Tesamorelin responders (n=193) and placebo (n=148) participants with available images were similar at baseline; most were Caucasian (83%) and male (87%).
Report a problemFND-3123731805
06HumanRandomized controlled trialEfficacy outcome
In adults with HIV and abdominal obesity, tesamorelin responders (visceral fat decrease of ≥8%) had a greater increase than placebo participants in the lean muscle area of all four truncal muscle groups.
In plain wordsIn adults with HIV and abdominal obesity, people who responded to tesamorelin had a larger rise in lean trunk muscle area than people on placebo.
Peptide
Tesamorelin
Outcome
IncreaseLean muscle area of four truncal muscle groups
Study
n = 341
Comparator
Placebo
Analysis
Exploratory
Outcome group
Body composition · Musculoskeletal
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Measurements
Lean area increase
0.64 to 1.08 centimeters2
four truncal muscle groups
Source sentences
Summary
Significant increases were also seen in total area of the rectus and psoas muscles (0.44 and 0.46 centimeters2; p<0.005), and in the lean muscle area of all four truncal muscle groups (0.64-1.08 centimeters2; p<0.005).
3 context sentences(design, population, supporting numbers)
Summary · context
compared to placebo.
Summary · context
Secondary, exploratory analysis of two previously completed randomized (2:1), clinical trials.
Summary · context
Tesamorelin responders (n=193) and placebo (n=148) participants with available images were similar at baseline; most were Caucasian (83%) and male (87%).
Report a problemFND-3123731806

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.